Central & South Asia
India ruling on cancer drug to be challenged
Order forcing Bayer to license its product to local company has huge repercussions for pharmaceutical giants.
Last Modified: 15 Mar 2012 04:50

A patent ruling in India is forcing German drug giant Bayer to license its anti-cancer medicine to an Indian company, Natco.

This will slash the price of the drug in India by up to 97 per cent. Bayer insists it will fight the ruling although Natco will be paying it six per cent royalty on the sales of Nexavar.

This is the first time such a ruling has been made in India and has massive repercussions for drug giants and their patents globally.

Prerna Suri reports from New Delhi.

Al Jazeera
Topics in this article
Featured on Al Jazeera
Swathes of the British electorate continue to show discontent with all things European, including immigration.
Astronomers have captured images of primordial galaxies that helped light up the cosmos after the Big Bang.
Critics assail British photographer's portrayal of indigenous people, but he says he's highlighting their plight.
As Western stars re-release 1980s charity hit, many Africans say it's a demeaning relic that can do more harm than good.
Remnants of deadly demonstrations to be displayed in a new museum, a year after protests pushed president out of power.
No one convicted after 58 people gunned down in cold blood in 2009 in the country's worst political mass killing.
While hosting the World Internet Conference, China tries Tiananmen activist for leaking 'state secrets' to US website.
Once staunchly anti-immigrant, some observers say the conservative US state could lead the way in documenting migrants.
NGOs say women without formal documentation are being imprisoned after giving birth in Malaysia.